NASDAQ : EXEL
Exelixis, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 66.2 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 16.40B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 16.93B |
| Enterprise Value | 15.69B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 244.01M |
| Shares Outstanding | 244.01M |
| Shares Change (YoY) | -7.47% |
| Shares Change (QoQ) | -1.51% |
| Owned by Insiders (%) | 2.67% |
| Owned by Institutions (%) | 97.07% |
| Float | 213.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 20.73 |
| Forward PE | 17.21 |
| PS Ratio | 6.78 |
| Forward PS | 6.09 |
| PB Ratio | 9.26 |
| P/TBV Ratio | 9.57 |
| P/FCF Ratio | 14.58 |
| P/OCF Ratio | 14.43 |
| PEG Ratio | 1.52 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 17.73 |
| EV / Sales | 6.29 |
| EV / EBITDA | 15.21 |
| EV / EBIT | 15.63 |
| EV / FCF | 13.52 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.21 |
| Quick Ratio | 2.99 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.14 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 44.32% |
| Return on Assets (ROA) | 23.52% |
| Return on Invested Capital (ROIC) | 73.33% |
| Return on Capital Employed (ROCE) | 47.78% |
| Weighted Average Cost of Capital (WACC) | 6.49% |
| Revenue Per Employee | $2.32M |
| Profits Per Employee | $821,857 |
| Employee Count | 1,077 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 3.26 |
Taxes
| Measure | Value |
|---|
| Income Tax | 180.70M |
| Effective Tax Rate | 16.95% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +75.98% |
| 50-Day Moving Average | 59.39 |
| 200-Day Moving Average | 50.91 |
| Relative Strength Index (RSI) | 81.65 |
| Average Volume (20 Days) | 2,412,820 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 27.31M |
| Short Previous Month | 28.18M |
| Short % of Shares Out | 11.19% |
| Short % of Float | 12.79% |
| Short Ratio (days to cover) | 11.69 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.50B |
| Gross Profit | 2.40B |
| Operating Income | 1.00B |
| Pretax Income | 1.07B |
| Net Income | 885.14M |
| EBITDA | 1.03B |
| EBIT | 1.00B |
| Earnings Per Share (EPS) | $3.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 892.02M |
| Total Debt | 162.20M |
| Net Cash | 1.24B |
| Net Cash Per Share | $5.07 |
| Equity (Book Value) | 1.83B |
| Book Value Per Share | 7.49 |
| Working Capital | 909.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.17B |
| Capital Expenditures | -11.97M |
| Depreciation & Amortization | 27.81M |
| Net Borrowing | n/a |
| Free Cash Flow | 1.16B |
| FCF Per Share | $4.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | 96.26% |
| Operating Margin | 40.21% |
| Pretax Margin | 42.69% |
| Profit Margin | 35.45% |
| EBITDA Margin | 41.33% |
| EBIT Margin | 40.21% |
| FCF Margin | 46.50% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 7.47% |
| Shareholder Yield | n/a |
| Earnings Yield | 4.82% |
| FCF Yield | 6.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $59.79 |
| Price Target Difference | -13.83% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 12.88% |
| EPS Growth Forecast (3Y) | 18.26% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.36 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |